iBio Inc. (IBIO)
NASDAQ: IBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $56.37M
- EPS (TTM)
- -$0.27
- Dividend yield
- None
- 52-week range
- 0.68 – 3.82
- Day range
- 0.7626 – 0.8266
- Volume / Avg
- 3.36M / 678.91K
- Beta
- —
- Shares outstanding
- 70.46M
52-week range
IBIO stock today
iBio (IBIO) closed at $0.8001 on Nov 20, down 0.11% (-$0.0009), versus the S&P 500's 3.70% decline. Volume was 5.0x the average at 3.36M shares, a sign of unusually heavy trading. Shares are 79.1% below their 52-week high of $3.82, set on Dec 10, 2025 and 17.7% above the 52-week low of $0.68, near the bottom of the past year's range.
IBIO is down 58.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.8%. iBio has posted a net loss over the last twelve months (EPS of -$0.27), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About iBio
Company profileiBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Martin B. Brenner D.V.M., Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 23
- Website
- ibioinc.com
Financial highlights
Full financialsIn fiscal 2026, iBio generated $100,000 in revenue, down 75.0% from fiscal 2025, its first annual decline since 2023. iBio reported a net loss of $33.0 million, compared with a loss of $18.4 million a year earlier. Operating margin was -35141.0%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $100.00K | $400.00K | $225.00K | $0 | $1.88M |
| Growth | -75.00% | +77.78% | — | -100.00% | -20.54% |
| Net income | $-33.04M | $-18.38M | $-24.91M | $-65.01M | $-50.30M |
| EPS (diluted) | $-0.32 | $-1.75 | $-6.50 | $-106.19 | $-5.78 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$5.69+611.16%
- Strong buy 1
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.05 vs $-0.06
- Surprise
- +16.67%
IBIO news
All IBIO news- iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific ConferencesGlobeNewswire
- iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate UpdateGlobeNewswire
- iBio to Participate in Upcoming Investor ConferencesGlobeNewswire
- iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 TherapyGlobeNewswire
iBio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KZIAKazia Therapeutics Limited ADR | 4.92 | -8.38% | $56.22M | vs IBIO |
| TENXTenax Therapeutics Inc. | 1.25 | -10.07% | $56.92M | vs IBIO |
| AZRAzora Therapeutics Inc. | 3.85 | -0.52% | $55.00M | vs IBIO |
| BOLDBoundless Bio Inc. | 2.32 | -2.52% | $54.78M | vs IBIO |
| RANIRani Therapeutics Holdings Inc. Class A | 0.5111 | -11.97% | $59.03M | vs IBIO |
| XLOXilio Therapeutics Inc. | 7.56 | -1.11% | $53.40M | vs IBIO |
| CTORCitius Oncology Inc. | 0.5035 | -10.95% | $53.25M | vs IBIO |
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs IBIO |
Indexes, lists and sector
iBio stock FAQ
What is iBio's stock price today?
IBIO last traded at $0.8001 as of Nov 20, 4:00 PM EST, down 0.11% on the day. Prices are delayed at least 15 minutes.
Does iBio pay a dividend?
No. iBio does not currently pay a regular cash dividend.
Who is iBio's CEO?
Dr. Martin B. Brenner D.V.M., Ph.D. is the chief executive officer of iBio Inc., which has about 23 employees.
Has IBIO ever split its stock?
Yes. The most recent IBIO stock split was a 1-for-20 split on Nov 29, 2023, one of 3 splits on record.
What is the IBIO 52-week high?
The 52-week high for IBIO is $3.82 and the 52-week low is $0.68. The stock is currently 79.1% below its high.